NMDAR Hypofunction Animal Models of Schizophrenia

Mechanisms of ketamine action as an antidepressant

(2018) P Zanos et al.   MOLECULAR PSYCHIATRY

Olanzapine Reverses MK-801-Induced Cognitive Deficits and Region-Specific Alterations of NMDA Receptor Subunits

(2018) Xiao Liu et al.   Frontiers in Behavioral Neuroscience

Agmatine-attenuated cognitive and social deficits in subchronic MK-801 model of schizophrenia in rats

(2018) Gokhan Unal et al.   Psychiatry and Clinical Psychopharmacology

Effect of clozapine on ketamine-induced deficits in attentional set shift task in mice

(2017) M. Szlachta et al.   PSYCHOPHARMACOLOGY

Ketamine: 50 Years of Modulating the Mind

(2016) Linda Li et al.   Frontiers in Human Neuroscience

Knockout of NMDA-receptors from parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801

(2016) A M Bygrave et al.   Translational Psychiatry

Frontal cortex and hippocampus neurotransmitter receptor complex level parallels spatial memory performance in the radial arm maze

(2015) Bharanidharan Shanmugasundaram et al.   BEHAVIOURAL BRAIN RESEARCH

Pyramidal Cell Selective Ablation of N-Methyl-D-Aspartate Receptor 1 Causes Increase in Cellular and Network Excitability

(2015) Valerie M. Tatard-Leitman et al.   BIOLOGICAL PSYCHIATRY

Inhibition of 14-3-3 Proteins Leads to Schizophrenia-Related Behavioral Phenotypes and Synaptic Defects in Mice

(2015) Molly Foote et al.   BIOLOGICAL PSYCHIATRY

Effects of prefrontal cortex and hippocampal NMDA NR1-subunit deletion on complex cognitive and social behaviors

(2015) Janet M. Finlay et al.   BRAIN RESEARCH

Neuregulin 1 Controls Glutamate Uptake by Up-regulating Excitatory Amino Acid Carrier 1 (EAAC1)

(2015) Ha-Nul Yu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Glutamate and dopamine in schizophrenia: An update for the 21st century

(2015) Oliver Howes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Disruption of mGluR5 in parvalbumin-positive interneurons induces core features of neurodevelopmental disorders

(2015) S A Barnes et al.   MOLECULAR PSYCHIATRY

Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

(2015) Meng-Lin Li et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

14-3-3ζ deficient mice in the BALB/c background display behavioural and anatomical defects associated with neurodevelopmental disorders

(2015) Xiangjun Xu et al.   Scientific Reports

Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia

(2015) Mark Slifstein et al.   JAMA Psychiatry

White Matter Injuries Induced by MK-801 in a Mouse Model of Schizophrenia Based on NMDA Antagonism

(2014) Yun Xiu et al.   Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology

The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome

(2014) Genoveva Uzunova et al.   Current Neuropharmacology

Unmet Needs in the Treatment of Schizophrenia

(2014) Leslie Citrome   JOURNAL OF CLINICAL PSYCHIATRY

14-3-3  and   Regulate Neurogenesis and Differentiation of Neuronal Progenitor Cells in the Developing Brain

(2014) K. Toyo-oka et al.   JOURNAL OF NEUROSCIENCE

14-3-3 Proteins Are Required for Hippocampal Long-Term Potentiation and Associative Learning and Memory

(2014) H. Qiao et al.   JOURNAL OF NEUROSCIENCE

Recent genetic findings in schizophrenia and their therapeutic relevance

(2014) Paul J Harrison   JOURNAL OF PSYCHOPHARMACOLOGY

De novo mutations in schizophrenia implicate synaptic networks

(2014) Menachem Fromer et al.   NATURE

A polygenic burden of rare disruptive mutations in schizophrenia

(2014) Shaun M. Purcell et al.   NATURE

Biological insights from 108 schizophrenia-associated genetic loci

(2014)   NATURE

Reverse Translation of Clinical Electrophysiological Biomarkers in Behaving Rodents under Acute and Chronic NMDA Receptor Antagonism

(2014) Elyse M Sullivan et al.   NEUROPSYCHOPHARMACOLOGY

Is There a Path Forward for mGlu2 Positive Allosteric Modulators for the Treatment of Schizophrenia?

(2013) Corey R. Hopkins   ACS Chemical Neuroscience

Heterogeneity of schizophrenia: Genetic and symptomatic factors

(2013) Sakae Takahashi   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

The effect of non-competitive NMDA receptor antagonist MK-801 on neuronal activity in rodent prefrontal cortex: an animal model for cognitive symptoms of schizophrenia

(2013) Kevin Blot et al.   JOURNAL OF PHYSIOLOGY-PARIS

The role of the hippocampo-prefrontal cortex system in phencyclidine-induced psychosis: A model for schizophrenia

(2013) Eiichi Jodo   JOURNAL OF PHYSIOLOGY-PARIS

NMDA Receptor Subunits in the Adult Rat Hippocampus Undergo Similar Changes after 5 Minutes in an Open Field and after LTP Induction

(2013) Maria Veronica Baez et al.   PLoS One

The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor

(2013) Bryan L. Roth et al.   PLoS One

Contribution of NMDA Receptor Hypofunction in Prefrontal and Cortical Excitatory Neurons to Schizophrenia-Like Phenotypes

(2013) Gregory R. Rompala et al.   PLoS One

NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia

(2013) Melissa A. Snyder et al.   Frontiers in Cellular Neuroscience

Increased NR2A:NR2B ratio compresses long-term depression range and constrains long-term memory

(2013) Zhenzhong Cui et al.   Scientific Reports

Locomotor hyperactivity in 14-3-3ζ KO mice is associated with dopamine transporter dysfunction

(2013) H Ramshaw et al.   Translational Psychiatry

Memory in aged mice is rescued by enhanced expression of the GluN2B subunit of the NMDA receptor

(2012) B.L. Brim et al.   BEHAVIOURAL BRAIN RESEARCH

Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation

(2012) Oliver D. Howes et al.   BRITISH JOURNAL OF PSYCHIATRY

Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice

(2012) Robert E. Featherstone et al.   NEUROBIOLOGY OF DISEASE

Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice

(2012) Manavi Chatterjee et al.   NEUROPHARMACOLOGY

The NMDA receptor as a target for cognitive enhancement

(2012) Graham L. Collingridge et al.   NEUROPHARMACOLOGY

Genetic Overexpression of NR2B Subunit Enhances Social Recognition Memory for Different Strains and Species

(2012) Stephanie A. Jacobs et al.   PLoS One

Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia

(2012) D. C. Javitt et al.   SCHIZOPHRENIA BULLETIN

PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis

(2012) V Wiescholleck et al.   Translational Psychiatry

Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia

(2011) Kara Kittelberger et al.   Brain Structure & Function

Animal models of schizophrenia

(2011) CA Jones et al.   BRITISH JOURNAL OF PHARMACOLOGY

NR2B-deficient mice are more sensitive to the locomotor stimulant and depressant effects of ethanol

(2011) K. A. Badanich et al.   GENES BRAIN AND BEHAVIOR

Synaptic changes in the brain of subjects with schizophrenia

(2011) Gábor Faludi et al.   INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

(2011) Bruce J. Kinon et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Neurodevelopmental and neuropsychiatric behaviour defects arise from 14-3-3ζ deficiency

(2011) P-S Cheah et al.   MOLECULAR PSYCHIATRY

A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior

(2011) M Carlén et al.   MOLECULAR PSYCHIATRY

Schizophrenia susceptibility pathway neuregulin 1–ErbB4 suppresses Src upregulation of NMDA receptors

(2011) Graham M Pitcher et al.   NATURE MEDICINE

mGluR5 and NMDA Receptors Drive the Experience- and Activity-Dependent NMDA Receptor NR2B to NR2A Subunit Switch

(2011) Jose A. Matta et al.   NEURON

Dopamine system dysregulation by the hippocampus: Implications for the pathophysiology and treatment of schizophrenia

(2011) Anthony A. Grace   NEUROPHARMACOLOGY

Glutamate signaling in the pathophysiology and therapy of schizophrenia

(2011) Chieh-Hsin Lin et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age-dependent manner

(2011) A. J. Ramsey et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia

(2011) Tamara Romón et al.   PSYCHOPHARMACOLOGY

Subanaesthetic Ketamine Treatment Alters Prefrontal Cortex Connectivity With Thalamus and Ascending Subcortical Systems

(2011) Neil Dawson et al.   SCHIZOPHRENIA BULLETIN

Effect of ‘chronic’ versus ‘acute’ ketamine administration and its ‘withdrawal’ effect on behavioural alterations in mice: Implications for experimental psychosis

(2010) Manavi Chatterjee et al.   BEHAVIOURAL BRAIN RESEARCH

Persisting cognitive deficits induced by low-dose, subchronic treatment with MK-801 in adolescent rats

(2010) Ji-Tao Li et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Expressions of Neuregulin 1βand ErbB4 in Prefrontal Cortex and Hippocampus of a Rat Schizophrenia Model Induced by Chronic MK-801 Administration

(2010) Yu Feng et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

NMDA Receptor Ablation on Parvalbumin-Positive Interneurons Impairs Hippocampal Synchrony, Spatial Representations, and Working Memory

(2010) Tatiana Korotkova et al.   NEURON

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism

(2010) Joanna C. Neill et al.   PHARMACOLOGY & THERAPEUTICS

The Role of Rodent Models in The Discovery of New Treatments for Schizophrenia: Updating Our Strategy

(2010) H. Moore   SCHIZOPHRENIA BULLETIN

Targeting 14-3-3 protein, difopein induces apoptosis of human glioma cells and suppresses tumor growth in mice

(2009) Weidong Cao et al.   APOPTOSIS

Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat

(2009) Claire E. McKibben et al.   BEHAVIOURAL BRAIN RESEARCH

Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia

(2009) T. B. Halene et al.   GENES BRAIN AND BEHAVIOR

(Epi)genomics and neurodevelopment in schizophrenia: monozygotic twins discordant for schizophrenia augment the search for disease-related (epi)genomic alterationsBased on a lecture during the joint meeting of the Genetics Society of Canada and the Society of Developmental Biology, 1 March 2008, at Banff Centre, Banff, Alberta, Canada, in recognition of the William F. Grant and Peter B. Moens Award of Excellence (2008) of the Genetics Society of Canada to Professor Shiva M. Singh.

(2009) Shiva M. Singh et al.   GENOME

Hyperdopaminergia and NMDA Receptor Hypofunction Disrupt Neural Phase Signaling

(2009) K. Dzirasa et al.   JOURNAL OF NEUROSCIENCE

Knockdown and overexpression of NR1 modulates NMDA receptor function

(2009) Maggie L. Kalev-Zylinska et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes

(2009) Juan E Belforte et al.   NATURE NEUROSCIENCE

Growth Factor-Dependent Trafficking of Cerebellar NMDA Receptors via Protein Kinase B/Akt Phosphorylation of NR2C

(2009) Bo-Shiun Chen et al.   NEURON

NMDA Receptor Hypofunction Leads to Generalized and Persistent Aberrant γ Oscillations Independent of Hyperlocomotion and the State of Consciousness

(2009) Tahir Hakami et al.   PLoS One

Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system

(2009) C. S. Barros et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Endogenous nonneuronal modulators of synaptic transmission control cortical slow oscillations in vivo

(2009) T. Fellin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for “NMDA antagonist modelling” of schizophrenia

(2009) Gary Gilmour et al.   PSYCHOPHARMACOLOGY

The Neurodevelopmental Hypothesis of Schizophrenia, Revisited

(2009) S. H. Fatemi et al.   SCHIZOPHRENIA BULLETIN

Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1–ErbB4 and DISC1

(2009) Hanna Jaaro-Peled et al.   TRENDS IN NEUROSCIENCES

Effects of subchronic phencyclidine (PCP) treatment on social behaviors and operant discrimination and reversal learning in C57BL/6J mice

(2009) Jonathan L. Brigman   Frontiers in Behavioral Neuroscience

Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls

(2008) Celia J. A. Morgan et al.   ADDICTION

Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat

(2008) Trisha A. Jenkins et al.   BEHAVIOURAL BRAIN RESEARCH

Neuregulin-1 Modulates Hippocampal Gamma Oscillations: Implications for Schizophrenia

(2008) André Fisahn et al.   CEREBRAL CORTEX

Identification of YWHAE, a gene encoding 14-3-3epsilon, as a possible susceptibility gene for schizophrenia

(2008) Masashi Ikeda et al.   HUMAN MOLECULAR GENETICS

Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation

(2008) Laura Gray et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Type III Neuregulin-1 Is Required for Normal Sensorimotor Gating, Memory-Related Behaviors, and Corticostriatal Circuit Components

(2008) Y.-J. J. Chen et al.   JOURNAL OF NEUROSCIENCE

Impaired discrimination learning in mice lacking the NMDA receptor NR2A subunit

(2008) J. L. Brigman et al.   LEARNING & MEMORY

Neuregulin 1 in neural development, synaptic plasticity and schizophrenia

(2008) Lin Mei et al.   NATURE REVIEWS NEUROSCIENCE

Contribution of Hippocampal and Extra-Hippocampal NR2B-Containing NMDA Receptors to Performance on Spatial Learning Tasks

(2008) Jakob von Engelhardt et al.   NEURON

Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression

(2008) Yukio Ago et al.   NEUROPHARMACOLOGY

Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity

(2008) Koji Yashiro et al.   NEUROPHARMACOLOGY

Target Identification for CNS Diseases by Transcriptional Profiling

(2008) C Anthony Altar et al.   NEUROPSYCHOPHARMACOLOGY

N-methyl-d-aspartic acid receptor antagonist–induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia

(2008) R.S. Ehrlichman et al.   NEUROSCIENCE

Low dose MK-801 reduces social investigation in mice

(2008) H ZOU et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia

(2008) Viviane Labrie et al.   PSYCHOPHARMACOLOGY

Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats

(2008) Alice Egerton et al.   PSYCHOPHARMACOLOGY

Genetic associations with schizophrenia: Meta-analyses of 12 candidate genes

(2008) Jiajun Shi et al.   SCHIZOPHRENIA RESEARCH

Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia

(2008) T. Walsh et al.   SCIENCE

Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia

(2008) Colin Kehrer   Frontiers in Molecular Neuroscience

N-Methyl d-Aspartate Receptor Antagonists Ketamine and MK-801 Induce Wake-Related Aberrant γ Oscillations in the Rat Neocortex

(2007) Didier Pinault   BIOLOGICAL PSYCHIATRY

A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats

(2007) Denise Manahan-Vaughan et al.   HIPPOCAMPUS

The cognitive effects of modulating the glycine site of the NMDA receptor with high-dose glycine in healthy controls

(2007) Colin Palmer et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL